evaluating the suitability of checkpoint inhibitors with biomarkers in patients with melanoma
Published 1 year ago • 60 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
14:32
evaluating the use of immune checkpoint inhibitors in melanoma
-
3:10
targeted therapy or checkpoint inhibitors in melanoma: which is better?
-
5:16
promising biomarkers to select patients for checkpoint inhibitor therapy in melanoma
-
1:44
immune checkpoint inhibitors in mcrpc
-
1:45
mechanisms of resistance to checkpoint inhibitors in melanoma
-
2:13
covid-19 vaccination in patients with rcc and melanoma treated with immune checkpoint inhibitors
-
8:17
immune checkpoint inhibitors
-
5:10
introduction to immune checkpoint inhibitor (ici) immunotherapy
-
3:06
melanoma monday: survival rates improving due to treatment advances
-
14:42
managing toxicities associated with immune-checkpoint inhibitors
-
1:57
managing the adverse events of immune checkpoint inhibitors
-
0:58
the future of immune checkpoint inhibition in melanoma
-
1:09
progress in treatment approaches for patients with melanoma
-
2:48
combining checkpoint blockade therapies in melanoma
-
2:45
correlation between cutaneous immune-related adverse events and os with immune checkpoint inhibitors
-
3:39
foxc1 as a novel prognostic biomarker in immune checkpoint inhibitor therapy
-
1:48
influence of new immunotherapy checkpoint inhibitors in melanoma
-
3:30
side effects of immune checkpoint inhibitors
-
1:27
analyzing the role of checkpoint inhibitors for the treatment of melanoma
-
3:18
immune checkpoint inhibitors and combination strategies for patients with gastric cancer
-
5:16
predictive biomarkers for immunotherapy in upper gi cancers